Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

Michael J. Keating(The University of Texas MD Anderson Cancer Center), Vinay Jain(Leeds General Infirmary), P. Santabárbara(Leeds General Infirmary), Maher Albitar(Genomic Health (United States)), Lee Brettman(Leeds General Infirmary), Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Bret Wacker(Leeds General Infirmary), John C. Byrd(The Ohio State University), Ian W. Flinn(Tennessee Oncology), Jacques‐Louis Binet(Leeds General Infirmary)
Blood
May 15, 2002
10.1182/blood.v99.10.3554
Cited by 946

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k